A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

PURPOSE: The purpose of the study was to evaluate safety and determine the maximum tolerated dose (MTD) of MEDI-575, a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor-α (PDGFRα), in patients with advanced solid tumors. METHODS: This phase I multicent...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Becerra, Carlos R., Conkling, Paul, Vogelzang, Nicholas, Wu, Hilary, Hong, Shengyan, Narwal, Rajesh, Liang, Meina, Tavakkoli, Fatemeh, Pandya, Naimish
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2014
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209236/
https://ncbi.nlm.nih.gov/pubmed/25149088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2567-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia